Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
The Chain of Custody in our labs is the unbroken link between the objects used in your research: your people, the animal models, the cell lines, reagents, compounds; the lab instruments and d...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
The Chain of Custody in our labs is the unbroken link between the objects used in your research: your people, the animal models, the cell lines, reagents, compounds; the lab instruments and d...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
Follow
